The complex interplay between viral infection and virus-activated inflammatory pathways with protease inhibitors (PIs) contributes to the increased risk of developing atherosclerosis and coronary artery disease in HIV-infected patients. Leflunomide is an antirheumatic drug whose administration to HIV-1-infected persons effectively decreases T-cell turnover and activation. In this study we have investigated the effects of leflunomide on dyslipidaemia and lipodistrophy induced by ritonavir in rodents.
Methods
Mice were administered ritonavir (5 mg/kg/day) alone or in combination with leflunomide (40 mg/kg/day) for 12 days. Expression of nuclear receptor and lipidogenetic genes was measured in liver and adipose tissues.
Results
Administration of the HIV PI ritonavir to mice increased plasma triacylglycerols, free fatty acids and cholesterol levels, and this effect was reverted by cotreatment with leflunomide. Ritonavir administration was associated with reduced epididymal fat/body weight ratio and increased liver content of triacylglycerols content. These effects were reverted by leuflunomide. Histopathology analysis shows that exposure to ritonavir causes inflammation of epididymal fat as demonstrated by dense leukocytes infiltration as well as by increased levels of proinflammatory mediators and reduced expression and activity of peroxisome proliferator-activated receptor-γ (PPAR-γ). Leflunomide reduced epididymal fat inflammatory-metabolic alteration induced by ritonavir and restored PPAR-γ expression in the epididymal fat.
Conclusions
We have shown that the anti-inflammatory drug leflunomide protects against ritonavir-induced inflammation and dysmetabolism in adipose tissue and might be a promising strategy in the setting of HIV-infected patients at risk for HIV-induced dyslipidaemia.
CarrA., SamarasK., ChisholmD.J., CooperD.A.Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet1998; 351: 1881–1883.
4.
DAD Study Group.Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med2007; 356: 1723–1735.
5.
GrahamN.M.Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr2000; 25: S4–S11.
6.
DistlerO., CooperD.A., DeckelbaumR.J., SturleyS.L.Hyperlipidemia and inhibitors of HIV protease. Curr Opin Clin Nutr Metab Care2001; 4: 99–103.
7.
HadiganC., MeigsJ.B., WilsonP.W.Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis2003; 36: 909–916.
8.
OrtizM., PoloniE.S., FurrerH.No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy. Swiss HIV Cohort Study. J Infect Dis2011; 203: 620–624.
9.
KoltaS., FlandreP., VanP.N.Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ ritonavir. Results of the MONARK trial. Curr HIV Res2011; 9: 31–39.
10.
GoetzmanE.S., TianL., NagyT.R.HIV protease inhibitor ritonavir induces lipoatrophy in male mice. AIDS Res Hum Retroviruses2003; 19: 1141–1150.
11.
DubéM.P., ParkerR.A., TebasP.Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS2005; 19: 1807–1818.
12.
FlintO.P., NoorM.A., HruzP.W.The role of protease inhibitors in the pathogenesis of HIV-associated lipodystrophy: cellular mechanisms and clinical implications. Toxicol Pathol2009; 37: 65–77.
13.
LagathuC., EustaceB., ProtM.Some HIV antiretrovirals increase oxidative stress and alter chemokine, cytokine or adiponectin production in human adipocytes and macrophages. Antivir Ther2007; 12: 489–500.
14.
KimM.J., LeclercqP., LanoyE.A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study. Antivir Ther2007; 12: 1273–1283.
15.
MaherB., LloydJ., WilkinsE.G.Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-alpha and TNF-receptor levels, and on metabolic parameters. Antivir Ther2004; 9: 879–887.
16.
ReadS.W., DeGreziaM., CicconeE.J.The effect of leflunomide on cycling and activation of T-cells in HIV-1-infected participants. PLoS ONE2010; 5: e11937.
17.
PériardD., TelentiA., SudreP.Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation1999; 100: 700–705.
18.
RiddleT.M., KuhelD.G., WoollettL.A., FichtenbaumC.J., HuiD.Y.HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory elementbinding proteins in the nucleus. J Biol Chem2001; 276: 37514–37519.
19.
MencarelliA., CiprianiS., RengaB.The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. PLoS ONE2010; 5: e13238.
20.
ShimomuraI., HammerR.E., IkemotoS., BrownM.S., GoldsteinJ.L.Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature1999; 401: 73–76.
21.
SekiyaM., YahagiN., MatsuzakaT.SREBP-1-independent regulation of lipogenic gene expression in adipocytes. J Lipid Res2007; 48: 1581–1591.
22.
PulfordK.A., SiposA., CordellJ.L., StrossW.P., MasonD.Y.Distribution of the CD68 macrophage/myeloid associated antigen. Int Immunol1990; 2: 973–980.
23.
DalenK.T., SchoonjansK., UlvenS.M.Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-gamma. Diabetes2004; 53: 1243–1252.
24.
BogackaI., XieH., BrayG.A., SmithS.R.The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care2004; 27: 1660–1667.
25.
BarbaroG.Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. Am J Ther2006; 13: 248–260.
26.
KotronenA., WesterbackaJ., BergholmR., PietiläinenK.H., Yki-JärvinenH.Liver fat in the metabolic syndrome. J Clin Endocrinol Metab2007; 92: 3490–3497.
CancelloR., TordjmanJ., PoitouC.Increased infiltration of macrophages in omental adipose tissue is associated with marked hepatic lesions in morbid human obesity. Diabetes2006; 55: 1554–1561.
29.
KolakM., WesterbackaJ., VelagapudiV.R.Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes2007; 56: 1960–1968.
30.
SevastianovaK., SutinenJ., KannistoK., HamstenA., RistolaM., Yki-JärvinenH.Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy. Am J Physiol Endocrinol Metab2008; 295: E85–E91.
31.
BastardJ.P., CaronM., VidalH.Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet2002; 359: 1026–1031.
32.
BrasaemleD.L.Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J Lipid Res2007; 48: 2547–2559.
33.
PistellP.J., GuptaS., KnightA.G.Metabolic and neurologic consequences of chronic lopinavir/ritonavir administration to C57BL/6 mice. Antiviral Res2010; 88: 334–342.
34.
RiddleT.M., FichtenbaumC.J., HuiD.Y.Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice. J Acquir Immune Defic Syndr2003; 33: 564–570.
35.
GoetzmanE.S., TianL., NagyT.R.HIV protease inhibitor ritonavir induces lipoatrophy in male mice. AIDS Res Hum Retroviruses2003; 19: 1141–1150.
36.
ProtM., HeripretL., Cardot-LecciaN.Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrob Agents Chemother2006; 50: 3998–4004.
37.
DonathM.Y., ShoelsonS.E.Type 2 diabetes as an inflammatory disease. Nat Rev Immunol2011; 11: 98–107.
38.
MannaS.K., MukhopadhyayA., AggarwalB.B.Leflunomide suppresses TNF-induced cellular responses: effects on NF-kappa B, activator protein-1, c-Jun N-terminal protein kinase, and apoptosis. J Immunol2000; 165: 5962–5969.
39.
AdamsM., ReginatoM.J., ShaoD., LazarM.A., ChatterjeeV.K.Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem1997; 272: 5128–5132.
40.
ZhouH., JarujaronS., GurleyE.C.HIV protease inhibitors increase TNF-alpha and IL-6 expression in macrophages: involvement of the RNA-binding protein HuR. Atherosclerosis2007; 195: e134–e143.
41.
SuganamiT., Tanimoto-KoyamaK., NishidaJ.Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol2007; 27: 84–91.
42.
CawthornW.P., SethiJ.K.TNF-alpha and adipocyte biology. FEBS Lett2008; 582: 117–131.
43.
EkinsS., KholodovychV., AiN.Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol2008; 74: 662–672.
44.
O'DonnellE.F., SailiK.S., KochD.C.The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS ONE2010; 5: e13128.
45.
LuoG., CunninghamM., KimS.CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos2002; 30: 795–804.
46.
ZhouJ., FebbraioM., WadaT.Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology2008; 134: 556–567.
47.
LeeJ.H., WadaT., FebbraioM.A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis. Gastroenterology2010; 139: 653–663.
48.
HazenbergM.D., OttoS.A., van BenthemB.H.Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS2003; 17: 1881–1888.
